Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

Phase 2

Completed

• Conditions: Pulmonary Disease, Chronic Obstructive
• Interventions: Drug: Atrovent® CFC inhalation aerosol; Drug: Ipratropium bromide HFA-134a inhalation aerosol; Drug: Placebo

• Registration Number: NCT02260011
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The objective of this study was to compare the bronchodilator efficacy and safety of ipratropium bromide HFA-134a inhalation aerosol and marketed, Atrovent® CFC Inhalation Aerosol in COPD patients

Detailed Description

Not available

Study Timeline

• Study Start: 2000-10
• Primary Completion: 2001-02
• Study First Submitted: 2014-09-11
• Status Verified: 2014-10
• Study First Submitted QC: 2014-10-07
• Last Update Submitted: 2014-10-07
• Study First Posted: 2014-10-09
• Last Update Posted: 2014-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

All patients must have a diagnosis of COPD and must meet the following spirometric criteria:

• Patients must have stable, moderate to severe airway obstruction with an FEV 1 (forced expiratory volume in the first second) <=65% of predicted normal and FEV1 <=70% of FVC (Forced Vital Capacity)

  • Males: Predicted normal FEV1=0.093 (height in inches) - 0.032(Age) - 1.343
  • Females: Predicted normal FEV1=0.085 (height in inches) - 0.025(Age) - 1.692

• Male or female patients 40 years of age or older

• Patients must have a smoking history of more than ten pack-years

• Patients must be able to demonstrate an improvement in FEV1 >=015% within one hour after inhalation of two puffs of Atrovent® inhalation aerosol (21 mcg per puff)

• Patients must be able to satisfactorily administer the medication, perform pulmonary function test and maintain records during the study period as required in the protocol

• All patients must sign an informed consent form prior to participation in the trial (i.e., prior to pre-study washout of their usual pulmonary medications and prior to fasting for laboratory tests)

Read More

Exclusion Criteria

• Patients with significant disease other than COPD were will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
• Patients with clinical relevant baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded
• All patients with serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L; serum glutamic pyruvic transaminase (SGPT) >80 IU/L, bilirubin >2.0 mg/dL, or creatinine >2.0 mg/dL will be excluded regardless of the clinical condition. Repeat laboratory evaluation will not to be conducted in these patients
• Patients with a history of asthma, allergic rhinitis or atopy or have a blood eosinophil count above 600/mm³. A repeat eosinophil count will not to be conducted in these patients
• Patients with a recent history (i.e., one year or less) of myocardial infarction
• Patients with a recent history (i.e., three years or less) of heart failure, patients with any cardiac arrhythmia requiring therapy, patients receiving any systemic beta blocker and patients on chronic daytime oxygen therapy
• Patients with known active tuberculosis
• Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma are allowed
• Patients with a history of life threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
• Patients who have undergone thoracotomy with pulmonary resection. Patients with a history or a thoracotomy for other reasons be evaluated as per exclusion criterion No. 1
• Patients with an upper respiratory tract infection or COPD exacerbation in the six weeks prior to screening visit (vist1) or during the baseline period
• Patients with known hypersensitivity to anticholinergic drugs
• Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction
• Patients with known narrow-angle glaucoma
• Patients who are on cromolyn sodium or nedocromil sodium
• Patients who are on antihistamines
• Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (e.g., oral contraceptives, intrauterine devices, diaphragm or Norplant®)
• Patients who have taken an investigational drug within one month or 6 half-lives (whichever is longer) of the drug prior to the screening visit or patients currently enrolled in other research study
• Patients with a history of and/or active alcohol or drug abuse

Exclusion criteria for patients with allergies

• Patients with active infectious rhinitis (common cold) as determined by history and physical
• Patients with upper or lower respiratory infection at screening

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Atrovent® CFC low	Atrovent® CFC inhalation aerosol	-
Ipratropium bromide HFA-134a high	Ipratropium bromide HFA-134a inhalation aerosol	-
Atrovent® CFC high	Atrovent® CFC inhalation aerosol	-
Placebo	Placebo	-
Ipratropium bromide HFA-134a low	Ipratropium bromide HFA-134a inhalation aerosol	-

Primary Outcome Measures

Name	Time	Method
Forced expiratory volume in 1 second (FEV1) response, calculated as area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 6 (AUC0-6)	After each drug administration

Secondary Outcome Measures

Name	Time	Method
Changes in peak FEV1 response	Baseline and after each drug administration
Onset of therapeutic FEV1 response	After each drug administration
Duration of therapeutic FEV1 response	After each drug administration
Time to peak FEV1 response	After each drug administration
Forced Vital Capacity (FVC) AUC0-6	After each drug administration
Changes from baseline in FEV1	Baseline and after each drug administration
Number of patients with adverse events	Up to 5 month after first drug administration
Peak FVC response	After each drug administration
Changes from baseline in FVC	Baseline and after each drug administration